Company Overview
We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Oxylanthanum Carbonate (OLC), for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494 for the treatment of acute kidney injury.
Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Email Alerts
Receive updates straight into your inbox
Stock Inforamtion
IR Contacts
Company
Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com
Investor Relations
T: 650-543-5470
ir@unicycive.com
Transfer Agent
Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003